StockNews.com Begins Coverage on OpGen (NASDAQ:OPGN)

StockNews.com initiated coverage on shares of OpGen (NASDAQ:OPGN) in a report released on Sunday morning. The firm issued a sell rating on the medical research company’s stock.

OpGen Stock Performance

NASDAQ OPGN opened at $0.64 on Friday. The firm’s 50 day moving average price is $0.54 and its 200-day moving average price is $0.50. OpGen has a 52-week low of $0.17 and a 52-week high of $3.84. The company has a market cap of $6.45 million, a PE ratio of -0.10 and a beta of -0.71.

Hedge Funds Weigh In On OpGen

A number of hedge funds and other institutional investors have recently modified their holdings of OPGN. HRT Financial LP acquired a new stake in OpGen in the fourth quarter valued at approximately $26,000. Citadel Advisors LLC raised its holdings in shares of OpGen by 571.0% in the third quarter. Citadel Advisors LLC now owns 100,773 shares of the medical research company’s stock worth $29,000 after buying an additional 85,754 shares during the last quarter. Dimensional Fund Advisors LP purchased a new position in shares of OpGen in the first quarter worth $49,000. Finally, Vanguard Group Inc. raised its holdings in shares of OpGen by 39.8% in the third quarter. Vanguard Group Inc. now owns 1,877,597 shares of the medical research company’s stock worth $537,000 after buying an additional 534,960 shares during the last quarter. 2.68% of the stock is currently owned by institutional investors.

About OpGen

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.